Compare CENTA & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENTA | CDNA |
|---|---|---|
| Founded | 1955 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 1996 | 2007 |
| Metric | CENTA | CDNA |
|---|---|---|
| Price | $34.67 | $50.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $36.75 | $28.00 |
| AVG Volume (30 Days) | 268.7K | ★ 983.3K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.41 | N/A |
| EPS | ★ 2.84 | 2.13 |
| Revenue | ★ $3,129,100,000.00 | $48,324,000.00 |
| Revenue This Year | $1.60 | $16.01 |
| Revenue Next Year | $2.04 | $11.31 |
| P/E Ratio | ★ $12.43 | $23.62 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $25.97 | $13.39 |
| 52 Week High | $40.80 | $53.67 |
| Indicator | CENTA | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 28.43 | 62.30 |
| Support Level | $33.34 | $45.74 |
| Resistance Level | $35.28 | $53.67 |
| Average True Range (ATR) | 0.89 | 2.43 |
| MACD | -0.34 | -0.44 |
| Stochastic Oscillator | 2.31 | 60.17 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.